You can buy or sell AKTX and other stocks, options, ETFs, and crypto commission-free!
Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Coversin, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
London, London & South East
52 Week High
52 Week Low
Akari Therapeutics PLC ADR
Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy.
Expected Mar 26, Pre-Market